Promotion

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

OPDP not happy with Diclegis promo

OPDP not happy with Diclegis promo

By

The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.

Co-pay cards OK for exchanges

Subscribers will be able to use co-pay cards on Obamacare exchanges.

OPDP expands "Bad Ad" with CME

OPDP expands "Bad Ad" with CME

By

The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.

Exclusive: Female duo takes agency helm ahead of Lehman's exit

Exclusive: Female duo takes agency helm ahead of Lehman's exit

By

Bruce Lehman, one of the longest-serving CEOs in the medical agency world, will retire at year's end, agency officials confirmed, spurring new leadership at the firm he co-founded in 1978, LehmanMillet.

Amped-up Victoza marketing hurts GLP-1 rivals

By

Novo redoubled its Victoza marketing efforts after a recent setback, and that's made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.

Business briefs: GlaxoSmithKline and Spectrum

GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.

I'll take DTC for $10 million, Alex

I'll take DTC for $10 million, Alex

The Wizards of White Oak are spending $10 million on DTC ad research. Is this a wise use of sparse agency resources?

Obesity marketing to stay same, despite new AMA designation

Obesity marketing to stay same, despite new AMA designation

By

Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.

McCann Health calls on Piasecki to head region

McCann Health calls on Piasecki to head region

By

Marci Piasecki was promoted to regional director, North America, with oversight over all five US professional agencies in McCann Health, the most senior of a series of personnel moves the network said are designed to bolster the operation.

Navidea deploying MSLs in launch of new diagnostic agent

Navidea deploying MSLs in launch of new diagnostic agent

By

Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.

Business briefs: BMS, Sanofi, UK Sunshine

BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.

Social media guru Gwee joins Chandler Chicco

Social media guru Gwee joins Chandler Chicco

By

Gwee, who pioneered pharma social media at Vertex before moving onto the agency side, is tasked with integrating digital and social strategies across the marketing and PR network's 14 agencies.

Business briefs: Chandler Chicco, Pfizer, FDA, Dainippon, CDC

Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.

Why SGLT-2s may put some spring into pharma spending

Why SGLT-2s may put some spring into pharma spending

Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.

Business briefs: Lundbeck and Otsuka; Omnicom; Vivus

Otsuka-Lundbeck CNS alliance extended to Alzheimer's drug; longtime DAS chief Tom Harrison steps down to chairman emeritus role

ProPublica's Charles Ornstein on life beyond Sunshine

ProPublica's Charles Ornstein on life beyond Sunshine

By

What will become of Dollars for Docs after the Sunshine provisions go into effect? We asked Charles Ornstein, who told us what's next for the project.

Rare disease awareness more than just a day for pharmas

Rare disease awareness more than just a day for pharmas

By

Industry observances of Rare Disease Awareness Day are getting more elaborate of late—perhaps not solely for altruistic reasons, as a third of NMEs approved by FDA over the past five years were for the treatment of rare diseases.

Havas hires WebMD sales chief to lead NY shop

Havas hires WebMD sales chief to lead NY shop

By

Dorothy Gemmell, who headed sales and sales operations at the portal, will take the reins at Havas Life New York.

Business briefs: Sobi and Savient; Novartis; Saatchi & Saatchi Wellness

Sobi and Savient Pharmaceuticals inked a co-promote agreement for RA drug Kineret in the US.

Business briefs: GlaxoSmithKline, Burson-Marsteller

GSK says 2013 will be a springboard for future growth, Burson-Marsteller hands out two new executive titles.

Business briefs: Novo Nordisk

Novo Nordisk promoted a quartet of US execs to SVP and announced sales growth of 18% for 2012.

Company news: Edelman, Pfizer, Publicis, Lippincott

Healthcare PR giant Dan Edelman dies; Pfizer says 'no comment' on breakup speculation; Publicis Healthcare snags a new SVP; Lippincott gives nurses a new drug diagnosis tool.

Company news: Biogen Idec, Merck

Biogen pulls ALS treatment from its pipeline, Merck resubmits cholesterol combo to FDA

Company news: AstraZeneca, Alcon, Novo Nordisk

AstraZeneca's 7,300 layoffs were not the last word for 2012, Alcon gets hit with an untitled letter from OPDP, and Novo creates an all-diabetic sports team

Elsevier samples experiential marketing

Elsevier samples experiential marketing

By

The company's first-ever road show has stimulated sales for its new ClinicalKey reference tool, grabbing the attention of time-harried doctors for as long as 30 minutes during the workday.

Company news: FDA, Shire, Bayer

A third-party review says FDA employees need more support; Shire launches rare disease research; and Bayer drops Schiff bid

Company news: Teva, Merck and BMS

Teva kicks off a succession plan early, and Merck launches Phase II trials of two all-oral hepatitis C regimens.

People news: Boston Scientific, Watson

Boston Scientific's new CEO takes office, Watson creates a generics management team

Company news: WebMD, Wolters Kluwer

WebMD named Global Crossing alum John Kritzmacher SVP of business operations, while Wolters Kluwer named a new president and CEO of medical research.

Email Newsletters